MDC (Metal-Drug Complex) is a cross-disciplinary platform engineered to meet the evolving needs of biotechnology, medicine, and defense through programmable coordination chemistry.
MDC empowers biotech firms with tunable drug scaffolds that extend molecular shelf-life, enable ligand-controlled logic, and provide adaptable architectures for modular therapeutic development.
Our platform transforms generic or underperforming compounds into targeted agents with improved solubility, uptake, and mechanism precision using metal-coordination chemistry.
MDC's framework accelerates hit-to-lead pipelines with programmable metal-ligand complexes that improve structure-activity relationship predictability and reduce development risk.
MDC complexes like Bi³⁺-Minocycline offer neuroprotective benefits through inflammation-targeted delivery and enhanced CNS penetration, addressing unmet needs in spinal cord injury and neurodegeneration.
We design metal-assisted logic gates (e.g., Ru⁴⁺-Doxorubicin) for tumor-selective toxicity, enabling next-gen precision cytotoxicity through microenvironment-triggered activation.
MDCs like Zn²⁺-Ivermectin increase viral protein binding and oral bioavailability, offering new paradigms for combatting respiratory and cytoplasmic-targeted viruses.
MDC serves as a logic-ready interface between molecular programming and biological systems, enabling a new class of chemically coded drugs adaptable to mission-specific profiles.
We offer rapid-deploy therapeutics and biodefense constructs using MDC logic, with tamper-proof microfoundry options, anomaly detection, and anti-replication security for defense partners.